These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7021161)

  • 1. Radioimmunoassay of urokinase for quantification of plasminogen activators released in ovarian tumour cultures.
    Astedt B; Holmberg L; Lecander I; Thorell J
    Eur J Cancer (1965); 1981 Feb; 17(2):239-44. PubMed ID: 7021161
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunoradiometric quantification of tissue plasminogen activator secreted by fetal organs. Comparison with urokinase.
    Holmberg L; Kristoffersson AC; Lecander I; Wallén P; Astedt B
    Scand J Clin Lab Invest; 1982 Jun; 42(4):347-54. PubMed ID: 6753100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on tissue culture plasminogen activator. II. The detection and assay of urokinase and plasminogen activator from LLC-PK cultures (porcine) by the synthetic substrate Nalpha-benzyloxycarbonyl-glycyl-glycyl-arginyl-4-methoxy-2-napthylamide.
    Huseby RM; Clavin SA; Smith RE; Hull RN; Smithwick EL
    Thromb Res; 1977 May; 10(5):679-87. PubMed ID: 882957
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture.
    Astedt B; Holmberg L
    Nature; 1976 Jun; 261(5561):595-7. PubMed ID: 819839
    [No Abstract]   [Full Text] [Related]  

  • 5. Direct fluorescent assay of urokinase and plasminogen activators of normal and malignant cells: kinetics and inhibitor profiles.
    Zimmerman M; Quigley JP; Ashe B; Dorn C; Goldfarb R; Troll W
    Proc Natl Acad Sci U S A; 1978 Feb; 75(2):750-3. PubMed ID: 204931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptation of plasminogen activator sequences to known protease structures.
    Strassburger W; Wollmer A; Pitts JE; Glover ID; Tickle IJ; Blundell TL; Steffens GJ; Günzler WA; Otting F; Flohé L
    FEBS Lett; 1983 Jul; 157(2):219-23. PubMed ID: 6345197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.
    Casslén B; Bossmar T; Lecander I; Astedt B
    Eur J Cancer; 1994; 30A(9):1302-9. PubMed ID: 7999418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assay method for single-chain urokinase-type plasminogen activator.
    Matsuo O; Ueshima S; Okada K; Fukao H; Ohgaki M; Watanabe R; Arimura H
    Hematol Pathol; 1989; 3(3):137-42. PubMed ID: 2531734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.
    Duffy MJ; O'Grady P; Devaney D; O'Siorain L; Fennelly JJ; Lijnen HJ
    Cancer; 1988 Aug; 62(3):531-3. PubMed ID: 3134120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture.
    Holmberg L; Lecander I; Persson B; Astedt B
    Biochim Biophys Acta; 1978 Nov; 544(1):128-37. PubMed ID: 152655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase plasminogen activator and prognosis in breast cancer.
    Duffy MJ; Reilly D; O'Sullivan C; O'Higgins N; Fennelly JJ
    Lancet; 1990 Jan; 335(8681):108. PubMed ID: 1967386
    [No Abstract]   [Full Text] [Related]  

  • 12. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium.
    Young TN; Rodriguez GC; Moser TL; Bast RC; Pizzo SV; Stack MS
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 1):1285-96. PubMed ID: 8178854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies.
    Nielsen LS; Grøndahl-Hansen J; Andreasen PA; Skriver L; Zeuthen J; Danø K
    J Immunoassay; 1986; 7(3):209-28. PubMed ID: 3091639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase-type plasminogen activator and its inhibitor PAI-1 in breast cancer: studies at both protein and mRNA level.
    Reilly D; Andreasen P; Duffy MJ
    Biochem Soc Trans; 1991 Feb; 19(1):44S. PubMed ID: 1903741
    [No Abstract]   [Full Text] [Related]  

  • 15. Microplate immunocapture assay for plasminogen activators and their specific inhibitors.
    Stephens R; Leung KC; Pöllänen J; Salonen EM; Vaheri A
    J Immunol Methods; 1987 Dec; 105(2):245-51. PubMed ID: 3121752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-related release of various molecular forms of urokinase in tissue culture.
    Astedt B; Barlow G; Holmberg L
    Thromb Res; 1977 Aug; 11(2):149-53. PubMed ID: 905967
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunological analysis of plasminogen activators from cultured human cancer cells.
    Naito S; Sueishi K; Hattori F; Tanaka K
    Virchows Arch A Pathol Anat Histol; 1980; 387(3):251-7. PubMed ID: 6779412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Enzymatic determination of plasminogen activators].
    Fischer BE
    Z Med Lab Diagn; 1988; 29(6):327-32. PubMed ID: 2973186
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasminogen activators in human malignant melanoma.
    Markus G; Kohga S; Camiolo SM; Madeja JM; Ambrus JL; Karakousis C
    J Natl Cancer Inst; 1984 Jun; 72(6):1213-22. PubMed ID: 6374238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activators in alveolar bone in man.
    Björlin G; Ljungnér H; Astedt B
    Acta Odontol Scand; 1986 Jun; 44(3):173-5. PubMed ID: 3461663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.